Interstitial cystitis

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

Retrieved on: 
Thursday, February 15, 2024
Managed Care, Biotechnology, Pharmaceutical, Health, Acquisition, Liver, Autoimmune disease, Income tax, Hepatology, FDA, Food, Endometriosis, PBC, Interest expense, Constipation, Annual general meeting, Short bowel syndrome, Safety, Society, GAAP, The Lancet, UEG, Pharmacokinetics, Food and Drug Administration, Primary biliary cholangitis, Interest, Patient, Disease, STARS, Phase, Interstitial cystitis, Trial of the century, Ageing, United European Gastroenterology, CIC, Research, SBS, Depreciation, Video game

Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.

Key Points: 
  • Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.
  • Operating expenses in the fourth quarter of 2023 were $80.0 million, compared to $38.8 million in the fourth quarter of 2022.
  • Adjusted EBITDA was $39.9 million in the fourth quarter of 2023, compared to $68.7 million in the fourth quarter of 2022.
  • Ironwood generated $35.8 million in cash from operations in the fourth quarter of 2023, compared to $79.2 million in cash from operations in the fourth quarter of 2022.

American Urological Association Names New Research Chair

Retrieved on: 
Thursday, January 11, 2024
Male, American Urological Association, Weill Cornell Medicine, Interstitial cystitis, MD, CPP, LUTS, Baylor College of Medicine, Baylor University, Chair, Signs and symptoms, NIH, AUA, Bangladesh Technical Education Board, The, Anesthesiology, Education, Management

BALTIMORE, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA) announced its Board of Directors has approved H. Henry Lai, MD, of Washington University School of Medicine, as the new Chair of the AUA Office of Research.

Key Points: 
  • BALTIMORE, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA) announced its Board of Directors has approved H. Henry Lai, MD, of Washington University School of Medicine, as the new Chair of the AUA Office of Research.
  • As Research Chair, Dr. Lai will lead the research components of the AUA and Urology Care Foundation missions, focusing on implementing strategic goals.
  • The main objective is to advance research in urologic diseases by engaging with the AUA Research Council and collaborating closely with the AUA Director of Research.
  • Specifically, the Chair partners with the AUA Office of Research and urologic research stakeholders to ensure the future of urology surgeon-scientists, enhance strategic programming in research funding and education, and support AUA research advocacy in public and private sectors.

The Endometriosis Treatment Center of America Redefines Care for Women Battling Interstitial Cystitis and Endometriosis

Retrieved on: 
Wednesday, November 22, 2023
FACOG, Woman, Interstitial cystitis, Frustration, ETCA, Approximation error, Pelvic pain, Quality of life, Interview, MD, Diagnosis, Birth control, Medical device, Endometriosis

ROYAL OAK, Mich., Nov. 21, 2023 /PRNewswire-PRWeb/ -- The Endometriosis Treatment Center of America (ETCA) is proud to announce its comprehensive approach to the diagnosis and treatment of Interstitial Cystitis in women with Endometriosis. These two conditions often present overlapping symptoms, posing a diagnostic challenge for many women and hindering access to appropriate care.

Key Points: 
  • The team at The Endometriosis Treatment Center of America recognizes the unique nature of these conditions and offers comprehensive care tailored to each individual's needs.
  • ROYAL OAK, Mich., Nov. 21, 2023 /PRNewswire-PRWeb/ -- The Endometriosis Treatment Center of America (ETCA) is proud to announce its comprehensive approach to the diagnosis and treatment of Interstitial Cystitis in women with Endometriosis.
  • These two conditions often present overlapping symptoms, posing a diagnostic challenge for many women and hindering access to appropriate care.
  • It's crucial for women experiencing these symptoms to seek specialized care to differentiate between the conditions and receive tailored treatment."

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Graft-versus-host disease, United European Gastroenterology, Short bowel syndrome, Constipation, Trial of the century, Income tax, Interstitial cystitis, Hepatology, Interest expense, EBITDA, Test Claimants in the Franked Investment Income Group Litigation v IRC, Liver, STARS, GAAP, Acquisition, SBS, Interest, PBC, Society, Pharmacokinetics, Phase, Clinical trial, Annual general meeting, Primary biliary cholangitis, Autoimmune disease, Depreciation, UEG, Safety, Total, CIC, Patient, Endometriosis, Pharmaceutical industry, Vaccine, Video game, Bookkeeping, Reinsurance, Bank, Ironwood, Nutrition

Total revenues in the third quarter of 2023 were $113.7 million, compared to $108.6 million in the third quarter of 2022.

Key Points: 
  • Total revenues in the third quarter of 2023 were $113.7 million, compared to $108.6 million in the third quarter of 2022.
  • Operating expenses in the third quarter of 2023 were $73.7 million, compared to $40.2 million in the third quarter of 2022.
  • Adjusted EBITDA was $49.1 million in the third quarter of 2023, compared to $68.8 million in the third quarter of 2022.
  • – Ironwood generated approximately $32.5 million in cash from operations in the third quarter of 2023, compared to $69.1 million in cash from operations in the third quarter of 2022.

Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

Retrieved on: 
Tuesday, August 8, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Natural borrowing limit, SBS, Workforce, Endometriosis, Total, IPR, Income tax, Interest, Test Claimants in the Franked Investment Income Group Litigation v IRC, PBC, Graft-versus-host disease, Clinical trial, GAAP, Research, Interest expense, Functional constipation, Short bowel syndrome, Trial of the century, Interstitial cystitis, Primary biliary cholangitis, EBITDA, Acquisition, STARS, Patient, Autoimmune disease, Liver, Depreciation, Phase, FDA, Hand, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Bank, Security (finance), Vaccine, Video game, Reinsurance, Bookkeeping, Ironwood

Ironwood intends to effect a squeeze-out merger under Swiss law to acquire the remaining outstanding VectivBio Shares in the second half of 2023.

Key Points: 
  • Ironwood intends to effect a squeeze-out merger under Swiss law to acquire the remaining outstanding VectivBio Shares in the second half of 2023.
  • Total revenues in the second quarter of 2023 were $107.4 million, compared to $97.2 million in the second quarter of 2022.
  • – Ironwood generated approximately $35.0 million in cash from operations in the second quarter of 2023, compared to $61.4 million in cash from operations in the second quarter of 2022.
  • Ironwood is increasing its 2023 U.S. LINZESS net sales and total revenue growth guidance and updating its adjusted EBITDA financial guidance.

Congressional Recognition for Historic Fibromyalgia Social Good Effort for Veterans and the Chronically Ill

Retrieved on: 
Saturday, July 1, 2023
2000 Goody's Body Pain 500, Anxiety, Syndrome, Education, Irritable bowel syndrome, Weakness, Hypoesthesia, Centers for Disease Control and Prevention, Brain, Language, Raynaud syndrome, Government, Physical, Interstitial cystitis, Congress, IBS, Nausea, Biophysical environment, Sleep, Chronic pain, Vertigo, Memory, Peripheral neuropathy, Fatigue, Nursing, Depression, Fibromyalgia

Kristal Kent shared with our team language from the proclamation request and outreach goals to get more supporters in various roles in our communities.

Key Points: 
  • Kristal Kent shared with our team language from the proclamation request and outreach goals to get more supporters in various roles in our communities.
  • "WHEREAS Fibromyalgia is a chronic-pain disorder that causes widespread body pain; affecting 3-5% of the population in the United States (Source: "Fibromyalgia - A Clinical Review" by Dr. Daniel J. Claw, April 16, 2014).
  • She added, "Congresswoman Nanette Diaz Barragan's recognition of the work we are doing to help others who suffer with Fibromyalgia means so much to our team.
  • I am so grateful for this opportunity and the support of my government representative."

MCI USA Association Solutions Welcomes Association of Pediatric Hematology/Oncology Nurses

Retrieved on: 
Tuesday, June 6, 2023
Workforce, Connect, Executive, Partnership, Society, CAE, Education, MSN, Medical Library Association, Nursing, Cancer, MCI, Strategic planning, Biopharmaceutical, Interstitial cystitis, Patient, RNA Society, Pediatrics, Hematology, Adolescence, It Happened Here, Zonta International, SITE, Disruption, Book, Woman

WASHINGTON, June 6, 2023 /PRNewswire-PRWeb/ -- MCI USA's Association Solutions division is pleased to welcome the Association of Pediatric Hematology/Oncology Nurses as a new full-service association management client. APHON provides leadership and expertise to pediatric hematology/oncology nurses by defining and promoting the highest standards of practice and care to the pediatric, adolescent, and young adult communities. Allison K. Summers, CAE, a global business expert and recognized association management professional, will serve as Executive Director.

Key Points: 
  • MCI USA's Association Solutions division is pleased to welcome the Association of Pediatric Hematology/Oncology Nurses as a new full-service association management client.
  • WASHINGTON, June 6, 2023 /PRNewswire-PRWeb/ -- MCI USA's Association Solutions division is pleased to welcome the Association of Pediatric Hematology/Oncology Nurses as a new full-service association management client.
  • "MCI USA will provide APHON with a full range of services, including access to global resources, strategic direction, excellent customer service, and sound accounting practices," said Carrie Hartin, President, Association Solutions, MCI USA.
  • MCI USA's cause and research-based client partners include RESOLVE: The National Infertility Association, Interstitial Cystitis Association, the Medical Library Association, the MSA Coalition, Pediatric & Congenital Electrophysiology Society and the RNA Society.

Women's Pelvic Health: Top 10 Things Women Want to Know about Sex and Vaginal Health but Are Reluctant to Ask

Retrieved on: 
Tuesday, May 16, 2023
Hair, Correlates of crime, Female, Urinary tract infection, Orgasm, DSM-IV codes, Pain, Patient, Risk, Personal lubricant, Menopause, Prevalence, Pelvic floor, HSDD, Faught, SOLVE, Male, BV, Urine, Vaginal discharge, Urination, Fear, Ageing, Research, Vagina, Intrauterine device, Lubricant, Proanthocyanidin, Bacteria, System, Woman, Skin, WHNP-BC, Hypoactive sexual desire disorder, Emmanuele A. Jannini, Incontinence, Bacterial vaginosis, Vanderbilt University, NCMP, Arousal, International Society for the Study of Vulvovaginal Disease, Ejaculation, Burns, Distress, Obstetrics, Obstetrics and gynaecology, Infection, Libido, DNP, Nutritional science, Interstitial cystitis, Friction, PAC, Abrasion, Dry, Probiotic, Pelvic floor dysfunction, Urology, Wine, Nursing, Birth control, Via

ATLANTA, May 16, 2023 /PRNewswire/ -- Committed to helping healthcare providers elevate the care of women at midlife and beyond, Solv Wellness regularly hosts webinars that enable peer-to-peer knowledge sharing. During their latest free educational webinar for providers, Brooke Faught, DNP, WHNP-BC, NCMP, FAANP, IF, and member of the Solv Wellness medical advisory board, emphasized the importance of driving conversations about sex and pelvic health with their patients to ensure women are not suffering in silence, especially with the broad availability of safe and effective solutions.

Key Points: 
  • It's so important, and we can even identify a lot of serious health concerns based on sexual symptoms and sexual complications."
  • In the webinar, Dr. Faught covered a variety of often-ignored topics about women's pelvic health.
  • She hopes sharing her experience will help foster more open dialogue between patients and their healthcare providers during office visits.
  • First, it's important to determine what's causing lack of interest in sex: low libido or hypoactive sexual desire disorder (HSDD).

Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance

Retrieved on: 
Thursday, May 4, 2023
Research, Clinical Trials, Biometrics, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Endometriosis, Income tax, Senior, Interest, Test Claimants in the Franked Investment Income Group Litigation v IRC, PBC, New Drug Application, Constipation, GAAP, Functional constipation, Trial of the century, IC/BPS, Interstitial cystitis, Primary biliary cholangitis, Shanda, EBITDA, Patient, AbbVie, Autoimmune disease, PDUFA, Liver, Depreciation, Ageing, Phase, FDA, Total, Safety, Pharmaceutical industry, Video game, Bookkeeping, Security (finance), Reinsurance, Ironwood

On April 10, 2023, Ironwood determined to eliminate the role of chief operating officer to streamline the executive leadership team.

Key Points: 
  • On April 10, 2023, Ironwood determined to eliminate the role of chief operating officer to streamline the executive leadership team.
  • Total revenues in the first quarter of 2023 were $104.1 million, compared to $97.5 million in the first quarter of 2022.
  • Operating expenses in the first quarter of 2023 were $44.0 million, compared to $39.7 million in the first quarter of 2022.
  • – Ironwood generated $80.2 million in cash from operations in the first quarter of 2023, compared to $64.1 million in cash from operations in the first quarter of 2022.

Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune

Retrieved on: 
Friday, April 28, 2023
LSE, IRAK4, Biotechnology, Atopic dermatitis, B cell, MRGPRX2, Interstitial cystitis, Patient, Series, Pivotal, Symbiosis, Inflammation, Pharmaceutical industry

LONDON, 27 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that the Series B financing for new Core Portfolio company, Evommune Inc. (“Evommune”), has closed.

Key Points: 
  • LONDON, 27 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that the Series B financing for new Core Portfolio company, Evommune Inc. (“Evommune”), has closed.
  • Arix co-led the $50 million round for Evommune, a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, investing $8.1 million (£6.6 million).
  • In connection with the financing, Arix will take a seat on Evommune’s board of directors.
  • Robert Lyne, CEO of Arix Bioscience, said: "We are pleased to have co-led this successful financing round for Evommune.